cours de bourse
14/08/2009 - 11:07:23|49.66 EUR 0.42 %
Partnership to develop immunotherapy treatments for respiratory allergies...
Stallergenes S.A. (Euronext Paris CAC small) plans to evaluate possible...
STALLERGENES, biopharmaceutical company
Major player in its market, Stallergenes established sublingual immunotherapy and remains the world leader in this area. Since 2003, the company is committed to the Stalair® development program, creating a new therapeutic class that covers 80% of respiratory allergies.
STALLERGENES celebrates its 50th Anniversary